medigraphic.com

2008, Number 4

<< Back Next >>

Arch Cardiol Mex 2008; 78 (4)

Low paraoxonase and arylesterase plasma activities in mexican patients with coronary artery disease

Gamboa R, Regalado JC, Huesca-Gómez C, Posadas-Romero C, Verdejo Paris J, Vargas-Alarcón G, Pérez-Méndez O

Language: Spanish
References: 41
Page: 360-368
PDF size: 140.76 Kb.


ABSTRACT

Purpose: To determine the Paraoxonase-1 (PON1) activity as well as its pheno- and genotypes at position 192 in Mexican subjects with diagnosis of coronary heart disease (CHD). Methods: We determined the PON1-192 polymorphism by PCR-RFLP, and serum PON1 activity, using either paraoxon (PONase activity) or phenylacetate (ARE activity) as substrates, in 155 clinically healthy individuals (control group), and 155 patients with at least one myocardial infarction (CHD group). The biochemical A/B phenotype was determined by the ratio of the NaCl 1 M-stimulated PONase activity divided by the ARE activity. Results: We found significantly lower PONase and ARE activities in CHD patients as compared to controls (233.1 ± 102.1 vs 295.8 ± 159.1 nmol/min/mL, and 103.1 ± 33.7 vs 220.2 ± 120.7. micromol/min/mL, respectively, p ‹ 0.05 for both). Allele and genotype frequencies for PON1-192 were similar in CHD patients and healthy controls. Moreover, in the control group, the PON1-192 Q/R genotype did not matched with the A/B phenotype as has been proposed by other studies. Conclusions: There were important differences in the ARE and PONase activities between Mexican CHD patients and controls, suggesting that PON1 activity could be a good marker of CHD risk, whereas PON1-192 lacks of value to assess such risk.


REFERENCES

  1. Assmann G, Schulte H, von Eckardstein, A, Huang Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11-S20.

  2. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohon SD, Schaefer MM, Castelli WP, et al: Factors associated with low and elevated plasma high-density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994; 35: 871-882.

  3. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN: Human serum Paraoxonase/Arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19: 2214-2225.

  4. Mackness M, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.

  5. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.

  6. Mackness M, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.

  7. Li WF, Costa LG, Richter RJ, Hagen T, Shih TM, Tward A, et al: Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000; 10: 767-779.

  8. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, et al: Evidence for association for paraoxonase gene polymorphisms and atherosclerotic disease. Atherosclerosis 2000; 149: 435-442.

  9. Shangera DK, Shara N, Aston CE, Kamboh MI: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067-1073.

  10. Karvonen J, Kauma H, Paivansalo M, Kesaniemi Y: Paraoxonase-1 gene Leu-Met55 and Gln-Arg192 polymorphisms are not associated with carotid artery atherosclerosis in a population-based cohort. Eur J Cardiovasc Prev Rehabil 2004; 6: 511-512.

  11. Sanghera DK, Saha N, Kamboh MI: The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 1998; 136: 217-223.

  12. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, et al: PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 2002; 32: 9-15.

  13. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Ritcher RJ, Schellenberg GD, et al: Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-2447.

  14. Jarvik GP, Hatsukami TS, Carlson C, Ritcher RJ, Jampsa R, Brophy VH, et al: Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 1465-1471.

  15. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457.

  16. Eckerson HW, Romson J, Wyte C, La Du BN: The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-227.

  17. Adkins S, Gan KN, Mody M, LaDu B: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.

  18. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-76.

  19. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J: Four paraoxonase polymorphism in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies. Lancet 2004; 363: 389-395.

  20. Rojas-García AE, Solís-Heredia MJ, Piña-Guzman L, López-Carrillo L, Quintanilla-Vega B: Genetic polymorphism and activity of PON1 in a Mexican population. Toxicol Appl Pharmacol 2005; 205: 282-289.

  21. Gamboa R, Zamora J, Rodriguez-Perez JM, Fragoso JM, Cardoso G, Posadas-Romero C, et al: Distribution of paraoxonase PON1 gene polymorphisms in Mexican populations. Its role in the lipid profile. Exp Mol Pathol 2006; 80: 85-90.

  22. Vargas-Alarcón G, Zamora J, Sánchez-García S, Rodriguez-Pérez, M, Cardoso G, Posadas-Romero C: Angiotensin-I-converting enzyme (ACE) insertion/deletion polymorphism in Mexican patients with coronary heart disease. Association with the disease but not with lipids levels. Exp Mol Pathol 2006; 81: 131-135.

  23. DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind B: A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. JAMA 1986; 256: 2372-2377.

  24. Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterease polymorphism. Am J Human Genet 1983; 35: 1126-1138.

  25. Gan KL, Smolen A, Eckerson HW, La Du BN: Protein purification of human serum paraoxonase/arylesterease. Evidence for one esterease catalyzing both activities. Drug Metab Dispos 1991; 19: 100-106.

  26. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 1: 1215.

  27. Motti C, Dessy M, Gnasso A, Irace C, Indigeno P, Angelucci CB, et al: A multiplex PCR-based DNA assay for the detection of paraoxonase gene cluster polymorphism. Atherosclerosis 2001; 158: 35-40.

  28. Browne RW, Koury ST, Marion S, Wilding G, Muti P, Trevisan M: Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin Chem 2007; 53: 310-317.

  29. Blatter MC, James RW, Messmer S, Barja F, Pometta D: Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993; 211: 871-879.

  30. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN: Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999; 19: 330-335.

  31. Sviridov D, Nestel PJ: Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 2007; 18: 157-163.

  32. Watanabe H , Söderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, Alagona C, et al: Decreased high-density lipoprotein (HDL) particle size, preß-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 2006; 26: 897-902.

  33. Morgan J, Carey C, Lincoff A, Capuzzi D: High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004; 6: 359-365.

  34. McEleveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH: Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32: 671-673.

  35. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high-density lipoprotein against low-density lipoprotein oxidative modification. FEBS Lett 1998; 423: 57-60.

  36. Ruiz J, Blanche H, James RW, Garin MJ, Vaisse C, Charpentier G, et al: Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-887.

  37. Mackness MI, Harty D, Bhatnagar D, Winocour TH, Arrol S, Ishola M, et al: Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199.

  38. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, et al: Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082-2088.

  39. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy V, Ritcher RJ, et al: Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002; 22: 1329-1333.

  40. Senti M, Tomas M, Anglada R, Elosua R, Marrugat J, Covas MI, et al: Interrelationship of smoking, paraoxonase activity and leisure-time physical activity: a population based-study. Eur J Intern Med 2003; 14: 178-184.

  41. Kleemola P, Freese R, Jauhiainen M, Pahlman R, Alfthan G, Mutanen M: Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002; 160: 425-432.




2020     |     www.medigraphic.com